Volume 151, Issue 1, Pages (October 2018)

Slides:

Advertisements

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Advertisements

Volume 12, Issue 9, Pages (September 2011)

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Volume 148, Issue 1, Pages (January 2018)

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 144, Issue 2, Pages (February 2017)

Volume 147, Issue 1, Pages 3-10 (October 2017)

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Targeting T Cell Co-receptors for Cancer Therapy

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

The development and use of vascular targeted therapy in ovarian cancer

Volume 145, Issue 2, Pages (May 2017)

Volume 387, Issue 10023, Pages (March 2016)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 2, Pages (November 2017)

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Volume 152, Issue 1, Pages (January 2019)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Volume 152, Issue 1, Pages (January 2019)

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Volume 152, Issue 1, Pages (January 2019)

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases Silvia Novello, MD, Carlos Camps, MD, Francesco.

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Volume 142, Issue 2, Pages (August 2016)

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 147, Issue 2, Pages (November 2017)

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

European Urology Oncology

Volume 115, Issue 1, Pages (October 2009)

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Volume 154, Issue 1, Pages (July 2019)

Bryan M. Burt, MD, Santiago Ocejo, MD, Carlos M

Presentation transcript:

Volume 151, Issue 1, Pages 46-52 (October 2018) Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer Kathleen N. Moore, David M. O'Malley, Ignace Vergote, Lainie P. Martin, Antonio Gonzalez-Martin, Karim Malek, Michael J. Birrer Gynecologic Oncology Volume 151, Issue 1, Pages 46-52 (October 2018) DOI: 10.1016/j.ygyno.2018.07.017 Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 1 Percent tumor change in target lesions by FRα expression. Data are presented from 15 patients as individuals with non-measurable disease were enrolled in the study. Asterix denotes patient still on study at time of final analyses. Dotted line in plots corresponds to 30% decrease in tumor size. Gynecologic Oncology 2018 151, 46-52DOI: (10.1016/j.ygyno.2018.07.017) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 2 Kaplan-Meier analysis of progression-free survival (PFS). Gynecologic Oncology 2018 151, 46-52DOI: (10.1016/j.ygyno.2018.07.017) Copyright © 2018 Elsevier Inc. Terms and Conditions